- Trial Status
- Patients randomised:
- 993
References
- Body SC, Mazer CD. Pro:Aprotinin Has a Good Efficacy and Safety Profile to other Alternatives for Prevention of Bleeding in Cardiac Surgery. Cardiovascular Anaesthesia 2006; 103:1354-1359.
- Beattie WS, Karkouti K. Con: Aprotinin Has a Good Efficacy and Safety Profile to other Alternatives for Prevention of Bleeding in Cardiac Surgery. Cardiovascular Anaesthesia 2006; 103:1359-1364.
- Mangano DT, the Multicenter Study of Perioperative Ischemia Research Group. Aspirin and Mortality from Coronary Bypass Surgery. N Engl J Med 2002; 347:1309-1317, Oct 24, 2002.
- United States Food and Drug Agency. Aprotinin Injection (marketed as Trasylol) [updated September 29, 2006].
- Harris G. FDA says Bayer failed to reveal drug risk study. (Published September 30 2006). New York Times
- Mangano D. T., Tudor I. C., Dietzel C., the Multicenter Study of Perioperative Ischemia Research Group and the Ischemia Research and Education Foundation. N Engl J Med 2006 Jan 26;354:353-65
- Sedrakyan A, Atkins D, Treasure T. The risk of aprotinin: a conflict of evidence. The Lancet 367; (9520):1376-1377
- Group. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71.
- Bélisle S, Hardy JF. Hemorrhage and the use of blood products after adult cardiac operations: myths and realities. Ann Thorac Surg 1996;62:1908.
- Mangano D. Aspirin and mortality from coronary bypass surgery. N Engl J Med. 2002;347:1309.
- The PEP Trial Collaborative Group. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. Lancet 2000;355:1295.
- Laupacis A, Fergusson D. Drugs to minimize perioperative blood loss in cardiac surgery: meta-analyses using perioperative blood transfusion as the outcome. Anesth Analg 1997;85:1258.
- Levi M, et al. Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints. Lancet 1999;354:1940.
- Tunis S, et al. Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy. JAMA 2003;290:1624.